Longboard Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 50
- Market Cap
- $1.3B
- Introduction
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on January 3, 2020 and is headquartered in San Diego, CA.
Global Clinical Trials for Dravet Syndrome Reviewed in 2024
A new report offers an overview of the clinical trial landscape for Dravet Syndrome, also known as Severe Myoclonic Epilepsy of Infancy, providing key data and analysis.
Bexicaserin Shows Sustained Seizure Reduction in Developmental Epileptic Encephalopathies
Bexicaserin demonstrated a 59.3% median reduction in countable motor seizures over 12 months in patients with developmental and epileptic encephalopathies (DEEs).
Longboard Pharmaceuticals Initiates Phase III Trial of Bexicaserin for Developmental and Epileptic Encephalopathies
Longboard Pharmaceuticals has commenced the Phase III DEEp OCEAN study to evaluate bexicaserin for seizures associated with developmental and epileptic encephalopathies (DEEs).
Longboard Pharmaceuticals Launches Phase 3 Trial of Bexicaserin for Developmental and Epileptic Encephalopathies
Longboard Pharmaceuticals has initiated the Phase 3 DEEp OCEAN study to evaluate bexicaserin for seizures associated with Developmental and Epileptic Encephalopathies (DEEs).
Longboard Pharmaceuticals Advances Bexicaserin for Dravet Syndrome
Longboard Pharmaceuticals initiated a Phase 3 clinical trial, DEEp SEA, to evaluate bexicaserin in Dravet syndrome patients aged 2-65 years.
Longboard Pharmaceuticals Initiates Phase 3 Trial of Bexicaserin for Dravet Syndrome
Longboard Pharmaceuticals has started a Phase 3 clinical trial, DEEp SEA, to assess bexicaserin in Dravet syndrome patients aged 2-65 years.
Epilepsy Pipeline Shows Promise with Novel Therapies in Clinical Trials
Over 90 epilepsy treatment therapies are under development by more than 75 companies globally, targeting various mechanisms of action and routes of administration.
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion, Bolstering Epilepsy Pipeline
Lundbeck will acquire Longboard Pharmaceuticals for $2.6 billion, gaining bexicaserin, a promising drug for developmental and epileptic encephalopathies (DEEs).
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion, Bolstering Dravet Syndrome Pipeline
Lundbeck announces a definitive agreement to acquire Longboard Pharmaceuticals for $2.6 billion in cash, expanding its neuroscience portfolio.
Longboard Pharmaceuticals Launches Phase 3 Trial of Bexicaserin for Dravet Syndrome
Longboard Pharmaceuticals has initiated a global Phase 3 trial, DEEp SEA, to evaluate bexicaserin for treating seizures associated with Dravet syndrome.